Comparable Outcomes in Early Hepatocellular Carcinomas Treated with Trans-Arterial Chemoembolization and Radiofrequency Ablation

The guidelines recommend radiofrequency ablation (RFA) for early hepatocellular carcinomas that are less than 3 cm and trans-arterial chemoembolization (TACE) for intermediate-stage tumors. Real-world patient and tumor factors commonly limit strict adherence to the guidelines. We aimed to compare th...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicines 2022-09, Vol.10 (10), p.2361
Main Authors: Tay, Benjamin Wei Rong, Huang, Daniel Q, Mark, Muthiah, Thong, Neo Wee, Guan Huei, Lee, Gee, Lim Seng, Cheng, Low How, Mei, Lee Yin, Thurairajah, Prem, Chen, Lim Jia, Ng, Cheng Han, Lim, Wen Hui, Tan, Darren Jun Hao, Maureen, Da Costa, Alfred, Kow Wei Chieh, Ganpathi, Iyer Shridar, Seng, Tan Poh, Young, Dan Yock
Format: Article
Language:English
Subjects:
Ablation
Hepatocellular carcinoma
Liver cancer
Liver diseases
Magnetic resonance imaging
Patients
Radiofrequency ablation
Statistical analysis
Survival
transarterial chemoembolization
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The guidelines recommend radiofrequency ablation (RFA) for early hepatocellular carcinomas that are less than 3 cm and trans-arterial chemoembolization (TACE) for intermediate-stage tumors. Real-world patient and tumor factors commonly limit strict adherence to the guidelines. We aimed to compare the clinical outcomes for TACE and RFA in early HCC. All consecutive patients from 2010 to 2014 that were treated with locoregional therapy at our institution were enrolled. The decision for TACE or RFA was based on tumor location, stage and technical accessibility for ablation. A subgroup analysis was performed for patients with tumors less than 3 cm. A total of 168 patients underwent TACE while 56 patients underwent RFA. Patients treated with TACE and RFA had 1- and 5-year survival rates of 84.7% and 39.8% versus 91.5% and 51.5%, respectively ( = 0.28). In tumors less than 3 cm, there was no significant difference in overall survival ( = 0.69), time to progression ( = 0.55), or number of treatment sessions required ( = 0.12). Radiofrequency ablation had a significantly higher chance of a complete response ( = 0.004). In conclusion, TACE may be selectively considered for early-stage hepatocellular carcinoma in patients unsuitable for other modalities.
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines10102361